630
Participants
Start Date
May 27, 2021
Primary Completion Date
January 27, 2023
Study Completion Date
January 27, 2023
Diagnosis of sensitive neuronopathy - phase 1
Search of positivity with anti-AGO antibodies test
Diagnosis of sensitive neuronopathy - phase 2
Title of anti-AGO antibodies
Comparison with Chi2 method
Clinical data from positive Argonaute (AGO) patients (age, sex, type of neuropathy, clinical manifestations of neuropathy, electroneuromyography , evolution of neuropathy, presence of associated autoimmune disease, response to possible immunomodulatory treatment) will be compared with those of negative patients using a Chi2 method for qualitative data.
Comparison of data with parametric Test (T-test)
Clinical data from positive Argonaute (AGO) patients (age, sex, type of neuropathy, clinical manifestations of neuropathy, electroneuromyography, evolution of neuropathy, presence of associated autoimmune disease, response to possible immunomodulatory treatment) will be compared with those of negative patients using a parametric test (T-test).
Comparison of data with non-parametric test (ANNOVA)
Clinical data from positive Argonaute (AGO) patients (age, sex, type of neuropathy, clinical manifestations of neuropathy, electroneuromyography , evolution of neuropathy, presence of associated autoimmune disease, response to possible immunomodulatory treatment) will be compared with those of negative patients using a non-parametric (ANNOVA).
CHU Saint-Etienne, Saint-Etienne
Centre Hospitalier Universitaire de Saint Etienne
OTHER